TFF Pharmaceuticals Inc

TFF Pharmaceuticals — 44th Annual ISHLT Meeting 2024

21 slides from TFF Pharmaceuticals's conference presentation, Apr 29, 2024

  1. Slide 1: TFF TAC Data Presented at 44th Annual ISHLT Meeting

    TFF TAC Data Presented at 44 th Annual ISHLT Meeting Late Breaking Abstract Oral Presentation April 13, 2024 BETTER DELIVERY, BETTER THERAPY | Powerful Drug Delivery Solutions NASDAQ: TFFP 1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement SPECIAL NOTE REGARDING FORWARD - LOOKING STATEMENTS This document contains forward - looking statements concerning TFF Pharmaceuticals, Inc. (“TFF”, “TFF Pharmaceuticals”, the “Company,” “we,” “us,” and “our”). The words “believe,” “may,” “will,” “potentially,” “estimate,” “con

  3. Slide 3: TFF TAC Clinical Data Update

    TFF TAC Clinical Data Update 3

  4. Slide 4: Introduction

    Introduction • Successful lung transplant requires significant systemic immunosuppression, but this comes at the cost of significant systemic toxicity • Significant renal impairment is one such example (~25% @5yrs post - lung transplant) • Substituting oral tacrolimus with Tacrolimus Inhalation Powd

  5. Slide 5: Inhalation Device for Lung Deposition

    Inhalation Device for Lung Deposition • TFF TAC utilizes Thin Film Freezing particle engineering technology (TFF Pharmaceuticals) • Dry powder (3.2μm diam) in 1mg & 0.25mg capsules, delivered by a simple handheld inhaler* • 1 - 2 x daily 5 *FDA Cleared Plastiape RS00 monodose device

  6. Slide 6: Phase 2 Study Design in Lung Transplant Patients

    6 Phase 2 Study Design in Lung Transplant Patients Tac dosing • Design : Open label study of TFF TAC lung transplant recipients requiring reduced tacrolimus blood levels due to renal toxicity • Duration : Part A : 12 weeks; Part B : optional safety extension • Endpoints : Safety & tolerability, rena

  7. Slide 7: Phase 2 Study Inclusion Criteria

    7 Phase 2 Study Inclusion Criteria • >18 years • >6 months post bilateral lung transplant • Triple immunosuppression • Stable (infection/rejection/reflux) • >40% predicted FEV1 • Creatinine >124µmol/L or eGFR < 45 mL/min/1.73m 2 * • Non - smoker FEV1: Forced Expiratory Volume in One Second eGFR: Est

  8. Slide 8: Baseline Characteristics and Demographics

    8 Baseline Characteristics and Demographics Disposition Time on TFF TAC (weeks) Years with kidney disease CLAD Years since transplant Race Sex Age (years) Patient Chose to proceed to Part B 49 5 No 9 W M 73 Pt 1 Chose to proceed to Part B 40 6 No 8 W F 73 Pt 2 Chose to proceed to Part B 33 4 No 5 W

  9. Slide 9: Data Suggest TFF TAC Prevents Rejection at a Fraction of Oral Tacrolimus Dose

    Data Suggest TFF TAC Prevents Rejection at a Fraction Of Oral Tacrolimus Dose With Reduced Systemic Exposures Reduction in systemic exposures to 2/3 are expected to decrease toxicities Trough TFF TAC/Oral Tac Blood Level Trough TFF TAC: Oral Tac Blood Level (ng/mL) Stable TFF TAC/Oral Tac Dose Stabl

  10. Slide 10: Blood Trough Levels

    Blood Trough Levels 16 14 12 10 8 6 4 2 0 TFF TAC Blood Level (ng/mL) 10 Data is from TFF - T2 - 001 pre - database lock; Data cut off date: 3/8/24 Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8 TFF TAC dose is reduced over time to protect the kidneys resulting in diminished tacrolimus blood levels; no acu

  11. Slide 11: Lower Doses of TFF TAC Result in Diminished Systemic Exposures

    Lower Doses of TFF TAC Result in Diminished Systemic Exposures and Less Pharmacokinetic Variability with Chronic Dosing Mean Tacrolimus in Blood - 6hr AUC Curve Day 1 doses: Patient 1=1. 5mg Patient 2=1.5 mg Patient 3=0.75 mg Day 85 doses: Patient 1=1 mg Patient 2=0.25 mg Patient 3=0.5 mg Trough Tac

  12. Slide 12: Renal Function Maintained

    Renal Function Maintained 60 55 50 45 40 35 30 25 20 15 10 eGFR (mL/min/1.73m 2 ) 12 Data is from TFF - T2 - 001 pre - database lock; Data cut off date: 3/8/24 Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8

  13. Slide 13: Normalization of Rejection-Related Gene Expression

    Normalization of Rejection - Related Gene Expression Following Transition From Oral Tacrolimus to TFF TAC Gene Expression Analysis Using MMDx • No gene expression evidence of rejection in 4/4 patients with available gene expression data on endobronchial biopsies: • Rejection - related genes normaliz

  14. Slide 14: Patient 1: MMDx Gene Expression Analysis

    Patient 1: MMDx Gene Expression Analysis Following Transition from Oral Tacrolimus to TFF TAC 0.61 0.31 Normal 0 0.23 Rejection 0.09 0.14 CLAD Biopsy 1: Oral Tac Day 0 Biopsy 2: TFF TAC Day 85 = Patient 1 Result = Patient 1 Result 14 Data is from TFF - T2 - 001 pre - database lock; Data cut off date

  15. Slide 15: MMDx Analysis: Increase in Normal Gene Expression

    MMDx Analysis: Increase in Normal Gene Expression TFF TAC Day 85 Normalness Rejection Late CLAD Oral Tacrolimus Day 0 Normalness Rejection Late CLAD 15 Data is from TFF - T2 - 001 pre - database lock; Data cut off date: 3/8/24

  16. Slide 16: Number of Abnormally Expressed Genes Decreased on TFF TAC

    Number of Abnormally Expressed Genes Decreased on TFF TAC Day 85 Day 0 Day 85 Day 0 Day 85 Day 0 Day 85 Day 0 Gene Sets Normal Normal Normal Normal Normal Normal Normal Normal Endothelium Related Normal Slightly Abnormal Normal Normal Slightly Abnormal Abnormal Slightly Abnormal Abnormal Rejection R

  17. Slide 17: Lung Function Remained Stable on TFF TAC

    Lung Function Remained Stable on TFF TAC 140 120 100 80 60 40 20 0 FEV 1 % predicted 17 Data is from TFF - T2 - 001 pre - database lock; Data cut off date: 3/8/24 Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8

  18. Slide 18: Adverse Events

    Adverse Events • Infections • COVID x4 • Complicated x1 with decreased lung FEV 1 • Lower Respiratory Tract Infection x1 picornavirus • Complicated by pleurisy, coronary angiogram pseudoaneurysm, atrial fibrillation, oral candida • Headache x2, tremor x1 • Increased creatinine x3 • Ultimately recove

  19. Slide 19: Summary

    Summary Efficacy • Successful transition of 8/8 from oral tac to TFF TAC • No evidence of acute rejection • No signs and symptoms suggestive of acute rejection • No use of pulse corticosteroids for treatment of rejection • No spirometry deterioration suggestive of acute rejection • No CXR findings s

  20. Slide 20: Conclusion

    Conclusion • TFF TAC shows promise as a simple, safe lung transplant immunosuppressant • Emerging experience, biomarker levels, gene expression & further immunological assessment will prove key in potentially enabling us to evaluate if even lower blood tac levels are possible • The current study may

  21. Slide 21: Thank You

    TFF, PHARMACEUTICALS. THANK YOU

TFF Pharmaceuticals — 44th Annual ISHLT Meeting 2024 on 6ix